Aerosolized pentamidine failure rate
Executive Summary
Is 13% on currently recommended dose schedule of 300 mg over four weeks for prophylaxis and treatment of HIV-related Pneumocystic carinii pneumonia, Henry Masur, chief of clinical medicine at NIH's Clinical Center, reported May 7. Longer term studies are showing 20-25% failure rates for the drug, Masur said.
You may also be interested in...
GeNeuro To Tackle Long COVID By Targeting Ancestor Viral Gene Activation
Switzerland’s GeNeuro will study whether its monoclonal antibody temelimab can prevent long-COVID, after data for the first time linked activation of human endogenous retroviruses (HERVs) to the condition and its associated neurological symptoms.
Executives On The Move: CFO Promoted At Novavax, Gilead Gets New Executive Vice President Of Research
Alpha Cognition, F2G and Immune Pharmaceuticals pick up new CEOs, and there is a new chief medical officer at Gemini Therapeutics.
FDA Guides On Virtual Inspections During COVID-19
Details of how the FDA plans to conduct remote evaluations of manufacturing facilities during the COVID-19 pandemic have been set out in guidance published by the US agency.